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Abstract Expression of catalytically active protein was detected 
in a murine mast cell line. The primary type of AChE mRNA 
produced by these cells was found to be the brain and muscle type 
by PCR amplification of alternative xons from the 3' of mast 
cells AChE cDNA. AChE was further found to be expressed in 
the HMC-1 the human mast cell precursor line. Furthermore, 
utilizing the single cell RT-PCR method we detected AChE 
mRNA expression in FcERI-positive single cells derived from 
human colonic mucosal biopsies. Our findings predict the involve- 
ment of mast cell AChE in neuronal-mast cell interactions. 
Key words: ACHE; Mast cell; Single-cell RT-PCR; 
Human precursor cell; Alternative splicing 
1. Introduction 
Mast cells are positioned in close association to peripheral 
nerves in many tissues [1]. Using an ultrastructural pproach, 
intimate interactions were observed between cholinergic nerves 
and mast cells both in the rat colon and in the hyperplastic 
neuronal network characteristic of Crohn's disease in humans 
[1,2]. As mast cells are present in such proximity to neurons, 
mast cell-nerve interactions may have important physiological 
functions. Recent studies have indeed shown that mast cells 
affect neuronal growth and polarity states and may induce the 
formation of contacts with nerves through long neurites [3]. In 
addition, in immunized guinea pigs, histamine and other mast 
cell granule factors were found to increase acetylcholine (ACh) 
secretion by cholinergic intestinal nerves through allergic re- 
sponses [4]. Reciprocally, ACh has been shown to induce mast 
cell degranulation and vice versa [5]. The mutual interactions 
between these two cell types might hence play an important role 
in the pathogenesis of several diseases uch as Crohn's disease 
and cholinergic urticaria [1,6 8]. 
Nerve cell terminals reaching neuromuscular junctions and 
cholinoceptive neurons of the central nervous system secrete 
the ACh hydrolysing enzyme acetylcholinesterase (ACHE). 
This enzyme is responsible for terminating ACh effects on the 
post-synaptic membrane [9] and can be linked to the cell mem- 
brane by different modes of attachment [10,11]. Within cells of 
the hematopoietic system, AChE is synthesized and secreted 
either in a hydrophobic phosphoinositide (PI)-linked form, as- 
sociated with the external cell surface or in globular hydrophilic 
forms [9 13]. These forms of AChE were shown by molecular 
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butyrylcholi- 
cloning to differ from each other at their 3'-regions and encode 
distinct C-terminal peptides [12,13]. The mature subunit of the 
hydrophilic enzyme is 583 amino acids (aa) long and essentially 
identical to the brain enzyme [13]. The amphyphilic Pl-linked 
form expressed in erythrocytes deviates from the other starting 
at aa 544 and is 24 aa smaller in size [13]. A third secretory 
'readthrough' form of ACHE, identified by molecular biology 
means, is predicted to be yet smaller in size, as its 26 aa long 
C-terminus, which deviates from the two others at the same 
point, lacks the capacity of (Pl)-linkage [14]. All three forms 
hydrolyze ACh rapidly, as was shown by enzyme purification 
[11] and cDNA transfection studies [14]. In the present study 
we demonstrate the expression of AChE in both human and 
mouse mast cells. The predominant mRNA type produced in 
mast cells is that one coding for the brain and muscle hydro- 
philic form of this enzyme. 
2. Materials and methods 
2.1. Cell culture 
1L-3 dependent mouse fetal iver-derived mast cells (MC-9) [15] were 
maintained in RPMI-1640 supplemented with 2 mM c-glutamine, 
2 mM non-essential amino acids, 100 U/ml penicillin, 100,ug/ml strepto- 
mycin (Gibco, Grand Island, NY), 50 HM fl-mercaptoethanol (Fisher 
Scientific, Medford, MA), 20 U/ml synthetic IL-3 and IL-4 (kindly 
provided by I. Clark-Lewis, Vancouver, Canada) with 10% fetal calf 
serum (FCS) (Bio-Lab, Jerusalem, Israel) or Gro-I (FCS medium re- 
placement, Biological Industries, Beth Haemek, Israel). Human imma- 
ture HMC-1 mast cells kindly provided by Joseph H. Butterfield, Mayo 
Foundation (Rochester, MN) were maintained inRPMI-1640 similarly 
supplemented to the MC-9 medium but without IL-3 and IL-4. 
2.2. Isolation and enrichment of human colonie mast cel& (approved by 
the local human subject committee, the 'Helsinkf committee) 
Normal mucosal biopsies incubated in saline overnight at 4°C were 
cleaned from mucus, incubated in RPMI-1640 medium supplemented 
with 25 mM HEPES and 1 mM dithiothreitol [16] and treated with 30 
U collagenase (Sigma, Israel). Percentage ofmast cells out of suspended 
cells filtered through a nylon wool column was determined by toluidine 
blue staining. Single cells were transferred in 10/11 of RPMI-1640 25 
mM HEPES into individual wells of Terasaki microtiter plate and were 
incubated for 6 h in 5% CO2 at 37°C [17]. 
2.3. RNA isolation and manipulation and RT-PCR 
RNA was isolated from 5 × l0  6 cells by RNA extraction-lysis buffer 
and centrifugation with CsC1 [18]. Reverse transcrption (37°C for 60 
min) was done with with 200 U of Moloney murine leukemia virus 
reverse transcriptase (RT) (Clonetech, Palo Alto, CA, USA) and 5/IM 
oligo(dT) primer, reaction buffer, 0.5 mM dNTP and 5 U of RNase 
inhibitor in 20/11 final volume. For PCR analysis, 2.5 U of Taq DNA 
polymerase, 3/IM of the appropriate PCR primers, 0.25 mM dNTE 
and reaction buffer (Perkin-Elmer, Norwalk, CT) were added to 100 
ng of total cDNA from each sample in a programmable thermal con- 
troller (MJ Research Inc.) all as described [17]. 
Single cells were lysed in 100/ll 10 mM Tris-HC| pH 8.0, 100 mM 
NaCI, 1 mM EDTA, 0.5% SDS and 100 jig proteinase K (10 min, 
37°C), after which 18/11 3 M NaC1 and 50 Hg oligo(dT) cellulose were 
added. Following overnight incubation at room temperature, the 
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oligo(dT) cellulose was washed thrice with 0.5 M NaCl, l0 mM Tris- 
HC1 pH 8.0, 1 mM EDTA and 0.1% SDS and once with 0.1 M NaCI, 
10 mM Tris-HCl pH 8.0, 1 mM EDTA and 0.1% SDS. RNA was eluted 
with 50 ,ul of 10 mM Tris-HCl pH 8.3 (10 min, room temp.), ethanol- 
precipitated in the presence of 5/~g tRNA, spun and washed with 70% 
ethanol. For PCR analyses dried RNA pellets were redissolved in RT 
buffer containing RNase inhibitor. 
2.4. Southern blot hybridization 
Amplified cDNA electrophoresed on agarose gels was transferred to 
Hybond-N membrane (Amersham, Arlington Heights, IL), hybridized 
with a 32P-labelled probe overnight, washed at 65°C for 20 rain in 
0.1 x SSC containing 0.1% SDS and autoradiographed. 
2.5. PCR primers 
The following PCR primers were employed: c~FceRI primers: 106+ 
5'-ATG GCT CCT GCC ATG GAA TCC CCT ACT-3'; and 519- 5'- 
GGT TCC ACT GTC TTC AAC TGT GGC AAT-3' [17]. Human 
AChE (exon 2+) 5'-GCT CGG CCG CCT CAG ACG CCG and (exon 
3-) 3'- TCC TCG CTC AGC TCA CGC TTG GG [13]. Murine AChE 
primers (exon 4) 1671+, 5'- CCA GAC CTG CGC CTT CTG GA; 
(exon 6) 1841-, 3'- GGT CTG AGC AGCGCT CCT GC; (exon 5) 
108- 3'-GAA GCC CGG AGT GGA GGA GG. Orientation of the 
primers is noted by + or - signs. 
2.6. ~'P probes 
One picomole ofa 25-mer oligodeoxynucleotide (routine ACHE, exon 
4) 1691 1713 5'-ATC GCT TTC TCC CCA AAT TGC TCA G was 
3' end labeled with [32P]dCTP by terminal deoxy-transferase (USB, 
Cleveland, OH, USA) [18]. cDNA probes for human and mouse 
c~FceRI, kindly provided by Dr. J.P. Kinet (National Institutes of 
Health, Bethesda, MD), were random prime labelling technique [18] up 
to a specific activity of 3 x 108 cpm//lg. AChE cDNA from human 
peripheral blood, was PCR amplified as above and 32p-labeled by ran- 
dom priming. Probes were hybridized at final concentrations of 5 x 10 ~' 
cpm/ml. 
2. 7. hnmunoprecipitation 
Five million cells washed once with 1 ml of DMEM-methionine-free 
medium (Biological Industries, Beth Haemek, Israel), were incubated 
(4 h, 37°C) in 5 ml medium containing 500/ICi [35S]methionine (Amer- 
sham). For immunoprecipitation cells were lysed in 500/11 cold lysis 
buffer (0.01 M Tris-HC1 pH 7.4, 1% deoxycholate, 1% Triton X-100, 
0.1% SDS, 0.15 M NaCI and 0.25 mM PMSF), homogenized, micro- 
fuged (30 rain at 4°C) and supernatants collected at 4°C. Immunopre- 
cipitation (overnight, 4°C) AE-2, a mouse monoclonal ntibody against 
human AChE (kindly provided by Dr. B.R Doctor, Washington, DC) 
or rabbit polyclonal antibody against human AChE (kindly provided 
by Dr. A. Shafferman, Israel Institute for Biological Research, Ness 
Ziona, Israel [19]), either preincubated or not with human ACHE. 
Protein-A Sepharose beads (10 mg/tube) (Sigma) were then added (3 
h with agitation, 4°C). Resultant imrnunocomplexes were boiled (10 
min in 0.5% SDS) and diluted five-fold with SDS-free buffer. Equal 35S 
counts from each mixture were reprecipitated using the same antibody. 
Precipitates boiled in Laemmli sample buffer containing 0.5% SDS, 
were electrophoresed on discontinuous 10% acrylamide-bisacrylamide 
SDS slab gels and exposed to Kodak X-Omat AR film at -70°C for 
noted times. 
2.8. Measurement of AChE catalytic activity 
For catalytic activity measurements, cells were grown for 14 days 
with FCS-free medium, washed with phosphate-buffered saline and 
homogenized in 200/~1 for l06 cells of 0.01 M Tris-HCl, 1 M NaC1, 1% 
Triton X-100, 1 mM EGTA pH 7.4. Homogenates were microfuged (20 
min, 4°C), and clear supernatants were collected. Spectrophotometric 
measurements of acetylthiocholine (ATCh) or butyrylthiocholine 
(BTCh) hydrolysis were assayed as previously detailed [13]. 
3. Results 
3.1. Cholinesterase activity 
Both acetylthiocholine (ATCh) and butyrylthiocholine 
(BTCh) were hydrolysed by mast cell extracts at rates of 1.2 and 
1.3 ~mol/min/106 cells, respectively. The ATCh hydrolysing 
activity was partially sensitive to the selective AChE inhibitor 
BW284C51 (40% at 1/~M) and resistant for the BuChE-selec- 
tive inhibitor iso-OMPA (10% inhibition at 10/IM). This iden- 
tified ca. 40% of this activity as ACHE. The BTCh activity was 
sensitive to iso-OMPA and insensitive to BW284C51, as ex- 
pected from mammalian BuChE (Table 1). Therefore mast cells 
were shown by this analysis to express both AChE and BuChE 
and in addition, yet unidentified protein(s) capable of hydroly- 
sing ATCh. 
3.2. Protein expression 
To clearly demonstrate hat mast cells indeed produce AChE 
and to exclude the possibility that this enzyme originated in 
serum, we used 35S labelling followed by immunoprecipitation. 
MC-9 cells produced polypeptides which were immunoprecip- 
itable with either rabbit polyclonal antibodies or mouse mono- 
clonal antibodies against human AChE (Fig. 1). Moreover, 
preincubating the polyclonal anti-AChE antibodies with unla- 
beled human ACHE, prior to the addition of the antibody to 
the lysate prevented the immunoprecipitation, confirming the 
identity of the precipitated protein as Ache [19]. Gel electro- 
phoresis and autoradiography revealed two main bands, one at 
a size between 55 kDa and 60 kDa and the other at a size over 
120 kDa. Interesting, several other weaker bands were observed 
at around 70 kDa. 
3.3. Type of MC-9 AChE 
Alternative splicing yields several mRNA products of the 
AChE gene [10-14]. This includes three splicing patterns at the 
3' region of the gene, leading to the expression of 3 protein 
isoforms that differ in their C-terminus. The AChE mRNAs 
produced by murine mast cells were identified by RT-PCR 
analyses using exon-specific oligonucleotide primers from the 
consensus regions of exon 4, 5 and 6 (Fig. 2). The cDNA- 
amplified products were then subjected to DNA blot hybridiza- 
tion analysis using a 25-base oligomer probe from the end of 
the common region of exon 4. Primers 4 and 6 yielded with 
MC-9 mRNA a single 170 bp band (Fig. 3A). This band fits 
the expected size of the amplified product of exon 4-6 splicing 
pattern. Digestion with SacI led to the disappearance of the 170 
bp band and the appearance of a shorter band, hence a more 
diffuse one, at a size of around 90 bp (Fig. 3B). As shown in 
Fig. 2, when using primers 4 and 6 for the PCR reaction, the 
splicing pattern of exon 4-5 should cause the appearance of a 
band at a size of 833 bp. However, such an amplified product 
from MC-9 mRNA was not detected. Our inability to detect he 
amplified product of 833 bp could be due to inefficient amplifi- 
cation of this longer fragment compared with that of the shorter 
170 bp fragment when using the same oligonucleotide primers. 
Therefore, an additional primer from exon 5 was used with 
Table l 
Cholinesterase activities of mast cell extracts 
Substrate ATCh BTCh 
mOD/min 0,947 0.340 
Hydrolysis rate ~mol/min/106 cells) 1.23 1.30 
BW284C51 [1/IM] (% inhibition) 40 none 
iso-OMPA [10 gtM] 10 98 
*Average of duplicate measurements at several time points. 
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primer 4 in search for the 170 bp amplification product repre- 
senting exon 4-5 splicing (Fig. 2). Using these primers the 
expected 170 bp amplification product was detected using 
mRNA derived from murine B cells, confirming the efficacy of 
this primer pair. However, this band was not detected with the 
same primers when mRNA from MC-9 cells was used (Fig. 3C). 
Thus, it can be concluded that AChE mRNA in MC-9 murine 
mast cells is primarily spliced with the Exon 4-Exon 6 pattern 
and does not contain exon 5. 
To determine whether AChE is expressed in human mast 
cells, mRNA was extracted from the human mast cell precursor 
cell line (HMC-I), reverse transcribed and amplified with 
human AChE specific primers. The amplified cDNA products 
were then subjected to DNA blot hybridization using a human 
AChE cDNA probe. As can be seen in Fig. 4, a band of the 
size of approximately 400 bp was detected as expected for the 
AChE cDNA amplification product. 
Thus human precursor mast cells also express the brain and 
muscle form of human AChE mRNA. 
3.4. Expression of  AChE in human intestinal FcsRI 
positive cells" 
In search of AChE mRNA in non-tumor, mature human 
mast cells in vivo, we examined whether AChE is expressed in 





Fig. 1. Identification of AChE in MC-9 cells. [35S]Methionine labeled 
MC-9 cells were lysed with lysis buffer as described in section 2. Im- 
munoprecipitates of MC-9 cell extracts were prepared with either poly- 
clonal rabbit anti-AChE (lane 1) or mouse monoclonal anti human 
AChE antibody (lane 3). Lane 2 = immunoprecipates obtained with 
rabbit anti-AChE preincubated with unlabeled human AChE prior to 
the addition of the antibody to the cell lysates. One representative 
experiment out of three. 
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Fig. 2. Exon-intron organization and putative PCR products of the 3' 
part of the murine AChE gene. Potential splice patterns of the 3' region 
of the gene are presented. Arrows present the location of the different 
PCR oligonucleotide primers. The probe is a 25-mer oligonucleotide. 
The size of the different possible splicing products are noted. 
FceR I-positive cells derived from human colonic mucosal biop- 
sies. Mast cells and other FcsRI positive cells which are in- 
volved in the allergic reaction in the intestine are dispersed 
between other cells in the tissue. Therefore, an enrichment of 
mast cells was performed. Using a published procedure for 
isolation of intestinal mast cells with nylon wool [16], positive 
toluidine blue staining was detected in only 2% of the isolated 
cells (data unshown). Therefore, this procedure was modified 
by the addition of overnight preincubation f the tissue at 4°C 
prior to the enzymatic digestion. Using this modification, 20% 
of the nylon wool column eluted cells were positively stained 
with toluidine blue. The RT-PCR single cell technique was 
thereafter used in order to determine the expression of AChE 
by individual cells [17]. Each single cell was then transferred 
into individual wells of Terasaki microtiter plate. The presence 
of a single cell in each well was verified by carefully scanning 
the wells with an inverted microscope. Messenger RNA was 
extracted from each cell and reverse transcribed with primers 
for the human FceRI ~ and the AChE genes. The cDNAs were 
then amplified by PCR. Bands at the sizes predicted for the 
amplified cDNA were obtained at around 500 bp and 400 bp 
for c~FceRI, and for ACHE, respectively (Fig. 5). The presence 
of AChE mRNA was observed in 7 out of 10 c~FceRI positive 
cells obtained from 3 different human colonal biopsies. We 
therefore concluded that AChE is most probably expressed in 
human intestinal mast cells. As the primers employed were 
from exons 4 and 6, this analysis further demonstrated a single 
primary splicing pattern for AChE mRNA from precursor and 
mature mast cells, i.e. the splicing pattern leading to the produc- 
tion of synaptic ACHE. 
4. Discussion 
In our present work we provided, for the first time, evidence 
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Fig. 3. Exon intron organization of AChE mRNA in murine MC-9 cells, mRNA isolated from MC-9 cells or murine B cells was reverse transcribed 
and amplified with oligonucleotide primers for the murine AChE gene. PCR products were separated by agarose gel electrophoresis, transferred to 
nylon hybridization membrane, hybridized with 32p end-labeled oligo and autoradiographed. (A) MC-9 mRNA amplified with primers 4 and 6. The 
size of the band is 170 bp. Lane I represents 1/10 the amount of cDNA as compared to II. (B) Digestion of the AChE 4-6 splicing product by Sael. 
The amplification product was digested overnight with I00 units of SacI restriction enzyme. Lane I = product of the PCR reaction with primers 4--6; 
lane II = the same PCR product digested with SacI. (C) Amplification with primers 4 and 5. cDNA from murine B cells (I and ll) and MC-9 cells 
(III and IV) was amplified with primers 4-5 (II and III) or 4-6 (1 and IV). 
detected cholinesterase activity in murine mast cells grown in 
a serum-free medium. By the use of specific inhibitors we dem- 
onstrated that some of the cholinesterase activity was probably 
due to BuChE activity, and some of it due to AChE activty. The 
coexpression of the two cholinestreases in one cell type is not 
surprising, since in other ceils of the hematopoietic system there 
is also coexpression of both enzyme types [20]. The detected 
AChE activity level was similar to that reported for leukocytes 
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[21]. To verify the findings on ACHE, which is the enzyme with 
expected neuronal functions, we searched for its protein and 
examined splicing pattern of the corresponding mRNA in mast 
cells. 
Immunoprecipitation experiments of nascently labelled pro- 
tein from MC-9 cells using polyclonal and monoclonal antibod- 
ies, revealed a prominent band of between 55 kDa and 60 kDa, 
several weaker bands above it up to around 75 kDa and a weak 
band at around 140-150 kDa. The larger band corresponds to 
the size expected from the dimer forms of ACHE. This raised 
the possibility that although the E4-E5 splicing pattern could 
not be observed in our RT-PCR analysis, it may exist in mast 
cells. Alternatively, or in addition, the heavy bands may reflect 
G2 dimers of the synaptic enzyme form, with or without struc- 
tural component(s). The appearance of the most prominent 
band at around 55-60 kDa and only weaker bands at the 
expected 70-75 kDa could be due to partial proteolysis of the 
enzyme, at the C-terminus that occurred uring extraction from 
the protease rich mast cells. Similar proteolysis of AChE at this 
site was previously observed after digestion with proteinase K 
[22]. Alternatively, or in addition, it could represent the slightly 
smaller 'readthrough' protein [14]. Selective antibodies hould 
be elicited to resolve this issue. 
Several transcripts can be produced by alternative splicing 
from the AChE gene [9,10,12-14]. These include three alterna- 
tive splicing patterns at the 3' region of the mRNA, leading to 
the production of three potential proteins differing in their 
C-termini [9,14]. One of these mRNAs encodes a phosphoinos- 
itide-membrane anchored protein, the main isoform expresssed 
in erythrocytes. The second codes for the brain and muscle 
protein, which is probably secreted and can form variable mul- 
timeric subunits, whereas, the third protein can only be secreted 
as monomers [14]. We found that the main transcript in mouse 
mast cells, like those of the hemapoietic cell lines [14], is the 
brain one, which fits the splicing pattern connecting exon 4 to 
6 and skipping exon 5. The protein coded by this mRNA can 





Fig. 4. Expression of AChE mRNAs in H MC-1 human immature mast 
cells, mRNA isolated from around a hundred HMC-I cells (using the 
method employed to isolate mRNA from single cells) reverse tran- 
scribed with human AChE primers, and then amplified. PCR products 
were separated by agarose gel electrophoresis, transferred to nylon 
hybridization membrane, hybridized with 32p-labeled cDNAs for 
human AChE and then autoradiographed for 17 h. 
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Fig. 5. Expression of AChE mRNAs in FcERI positive cells from 
human colonic mucosa. Single cells from mast cell-enriched fractions 
of human colonic mucosal biopsies were carefully divided into Terasaki 
plates, mRNA from each of the single cells was individually reverse- 
transcribed with human ~FceRI and AChE primers and then PCR- 
amplified (30 cycles). PCR products were separated in agarose gels by 
electrophoresis, transferred to nylon hybridization membrane, hybrid- 
ized with 32p-labeled cDNAs for human ~FceRI, and AChE and au- 
toradiographed for 17 h. 
cellular membranes. However, the main polypeptide im- 
munoprecipitated from mast cells was somewhat smaller from 
the brain and muscle form peptide, either through proteolytic 
cleavage or, perhaps, reflecting the readthrough protein. More- 
over, our immunoprecipatation data demonstrated the pres- 
ence of dimers, which raises the possibility that very low levels 
of mRNA with the exon 4 to exon 5 splicing pattern also exist 
in these cells, producing GPI-linked dimers. This analysis there- 
fore, leaves the question of the exact nature of the mast cell 
AChE open. 
Next we decided to examine whether AChE is expressed in 
human mast cells. First, AChE mRNA was detected in a 
human mast cell precursor line (HMC-1). In view of the consid- 
erable heterogeneity between mast cells from different organs 
[23], and since mast cell neuronal interactions were observed in 
the intestine [2,24], we searched for AChE expression i  human 
intestinal-derived FceRI cells by using the single cell RT-PCR 
methodology. We observed a close correlation between the 
percentage of the toluidine-positive c lls and the percentage of 
cells expressing FceRI, which sustains the assumption that the 
majority of the isolated FceRI-positive cells were mast cells. 
Furthermore, we find that cells isolated by the same method 
contain the c-kit mRNA which is known to be expressed in 
mast cells but not in other FcERI expressing cells such as 
basophils (Ligumski, M., Kuperstein, V., Nehushtan, H. and 
Razin, E., unpublished results). AChE mRNA was expressed 
in most (7 out of 10) of the FceRI-positive cells derived from 
three different human colon biopsies. Therefore AChE is most 
probably expressed in human intestinal mast cells. 
Currently we can only speculate on the physiological role 
played by AChE expressed by mast cells. In other non-neuronal 
cells synthesizing ACHE, such as myocytes, this enzyme is per- 
sumably responsible for the degradating of ACh released by 
cholinergic neurons [9,10]. A similar role for mast cell AChE 
seems logical. Several works demonstrated that ACh induced 
mast cell degranulation can take place only in immunologicaly 
stimulated cells (for a detailed iscussion of this issue see [25]). 
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In addition, it was shown that antigenic stimulation that led to 
the degranulation of mast cells caused an increase in ACh 
release from intestinal nerve cells [4]. Thus a possible positive 
feedback cycle can exist: activation of mast cells by antigen can 
increase ACh release by neurons, and this response may lead 
to further degranulation of mast cells. 
Interactions between mast cells and neurons can possibly 
contribute to the pathogenesis of many diseases, including al- 
lergic and chronic inflammatory ones like Crohn's disease [1]. 
The most direct link between a disease and mast cell-neuron 
interactions has been shown for cholinergic urticaria. In one 
patient with this disease, the immediate type hypersensitivity 
reaction to copper was found to be correlated with increased 
mast cell ACh receptor concentrations [8]. 
Acetylcholine l vels in the extracellular space are controlled 
not only by the amount released from nerve cells, but also by 
the rate of its degradation, mainly by ACHE. Therefore, mast 
cell-produced AChE can serve an important role in the modu- 
lation of mast cell-neuron interactions. Contribution to our 
understanding of the pathogenesis of diseases linked to neuro-  
allergic interactions might be achieved through the study of 
mast cell produced AChE from individuals with these diseases. 
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